Loading clinical trials...
Loading clinical trials...
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs)
Conditions
Interventions
cisplatin
ifosfamide
+4 more
Locations
1
Hong Kong
The University of Hong Kong
Hong Kong, Hong Kong
Start Date
February 24, 2017
Primary Completion Date
July 31, 2021
Completion Date
February 28, 2022
Last Updated
June 11, 2018
NCT07389616
NCT07356245
NCT07353840
NCT04068597
NCT06072131
NCT04083495
Lead Sponsor
The University of Hong Kong
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions